Measures of tau and beta-amyloid in CSF, MTL atrophy on MRI, and

Measures of tau and beta-amyloid in CSF, MTL atrophy on MRI, and performance on delayed memory tasks were extracted from the papers or obtained from the investigators.

Results. Twenty-one MRI studies and 14 CSF Studies

were retrieved. The effect sizes of total tau (t-tau), phosphorylated tau (p-tau) and amyloid beta 42 (a beta 42) ranged from 0.91 to 1.11. The effect size of MTL atrophy was 0.75. Memory performance had an effect size of 1.06. MTL atrophy and memory impairment tended to increase Selleck PHA-848125 when assessed closer to the moment of diagnosis, whereas effect sizes of CSF biomarkers tended to increase when assessed longer before the diagnosis.

Conclusions. Memory impairment is a more accurate predictor of early AD than atrophy of MTL on MRI, whereas CSF abnormalities

and memory impairment are about equally predictive. Consequently, the CSF and MRI biomarkers are not very sensitive to preclinical AD. CSF markers remain promising, but studies with long follow-up periods in elderly subjects who are normal at baseline are needed to evaluate this promise.”
“Background. Panic disorder (PD) is generally considered to be a chronic or intermittent disorder. This view may be biased because of a lack of general population studies investigating panic from the onset of an episode onwards. Data regarding the course of subthreshold panic disorder (sub-PD) and predictors of its course are lacking.

Method. Using data from a large community-based survey, the Netherlands Rapamycin molecular weight Mental Health and Incidence Study (NEMESIS), OICR-9429 that retrospectively assessed

the 2-year course of panic with a Life Chart Interview (LCI), this Study investigated remission, chronicity and recurrence in subjects with new episodes of PD or sub-PD. Predictor variables of remission consisted of sociodemographics, psychobiological, environmental, psychiatric and panic-related factors.

Results. In PD, remission of panic attacks occurred in 64.5% of subjects, mean time to remission was 5.7 months, and the remission rate was 5.8/100 person-months. In 43.3%, of subjects panic was still present after 1 year. Recurrence of panic attacks occurred in 21.4%, of those with PD who had achieved remission and for whom sufficient follow-tip time was available. In general, the Course of sub-PD was more favourable. Predictors of remission were female gender, the absence of ongoing difficulties, subthreshold panic and a low initial frequency of attacks.

Conclusions. These results Suggest that the Course of panic is diverse in the general population, thereby underlining the need for accurate predictors. This requires further research including biological data and additional psychological data. In addition, given the large proportion with a relapse, relapse prevention should be part of any treatment programme.

Comments are closed.